Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have body mass index (BMI) ≥30.0 kilograms per square meter (kg/m²), or ≥27.0 kg/m² with at least one of the following:
* hypertension
* dyslipidemia
* obstructive sleep apnea, or
* cardiovascular disease
History of at least one unsuccessful dietary effort to reduce body weight
Have index knee pain for \>12 weeks prior to screening, and presence of index knee pain for \>15 days over the previous month
Have knee X-ray with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3) per central reading at screening
Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA.
Previously diagnosed with OSA
Have AHI ≥15 on polysomnography at screening (definition of moderate-to-severe OSA)
For participants not on positive airway pressure (PAP) therapy: unable or unwilling to use PAP therapy and have not used PAP for at least 4 weeks prior to screening.
If on PAP therapy, have been on PAP therapy for at least 3 consecutive months prior to screening, and willing to temporarily stop using PAP therapy for approximately 7 days prior to each of the sleep study (PSG) visits.
Have completed the final treatment visit of GZBJ Week 80.
You may not be if
Have a self-reported or documented change in body weight \>5 kg (11 pounds) within 90 days.
Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
Have a prior or planned surgical treatment for obesity.
Have diabetes mellitus.
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have had pancreatitis.
Have had steroid joint injections within 90 days of screening.
Have had other joint injections and procedures within 6 months of screening.
Have joint disease other than osteoarthritis.
Use stimulants (for example, modafinil, armodafinil, solriamfetol, pitolisant, amphetamine) less than 3 months prior to screening.
Use hypnotics, mirtazapine, opioids, trazodone, and zonisamide less than 3 months prior to screening.
Use a dental appliance or other device to treat OSA other than PAP therapy.
Have had study intervention discontinuation.
Have had permanent dose reduction.
Clareo Health | A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
